Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000518412 | SCV000613964 | uncertain significance | not provided | 2017-06-30 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764622 | SCV000895730 | uncertain significance | Merosin deficient congenital muscular dystrophy; Muscular dystrophy, limb-girdle, autosomal recessive 23 | 2022-03-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000815597 | SCV000956058 | likely benign | LAMA2-related muscular dystrophy | 2024-01-21 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000518412 | SCV001713375 | uncertain significance | not provided | 2020-01-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000518412 | SCV001988995 | uncertain significance | not provided | 2019-07-31 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In-silico analysis, which includes splice predictors and evolutionary conservation, is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function |